Lumexa Imaging (NASDAQ:LMRI – Get Free Report) was upgraded by investment analysts at KeyCorp to a “strong-buy” rating in a research note issued to investors on Thursday, Zacks reports.
Other equities research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d)” rating on shares of Lumexa Imaging in a research note on Tuesday. Barclays boosted their price objective on Lumexa Imaging from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Friday, August 28th. Wall Street Zen cut Lumexa Imaging from a “buy” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Deutsche Bank Aktiengesellschaft set a $16.00 price objective on shares of Lumexa Imaging in a report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.50.
Read Our Latest Stock Report on LMRI
Lumexa Imaging Stock Down 2.6%
Lumexa Imaging (NASDAQ:LMRI – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.03 by $0.17. The firm had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. As a group, equities analysts expect that Lumexa Imaging will post 0.25 earnings per share for the current fiscal year.
Institutional Trading of Lumexa Imaging
Institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC boosted its position in Lumexa Imaging by 506.9% in the second quarter. Squarepoint Ops LLC now owns 79,934 shares of the company’s stock valued at $902,000 after buying an additional 66,763 shares during the last quarter. Readystate Asset Management LP lifted its stake in Lumexa Imaging by 11.5% in the second quarter. Readystate Asset Management LP now owns 250,533 shares of the company’s stock worth $2,826,000 after acquiring an additional 25,778 shares during the last quarter. AXQ Capital LP purchased a new stake in shares of Lumexa Imaging in the 2nd quarter valued at approximately $128,000. Bank of America Corp DE purchased a new stake in shares of Lumexa Imaging in the 2nd quarter valued at approximately $200,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Lumexa Imaging during the 2nd quarter worth $24,269,000.
Lumexa Imaging Company Profile
Lumexa Imaging, Inc (NASDAQ: LMRI) is an outpatient diagnostic imaging company that provides medical imaging services to patients and referring healthcare providers in the United States. Its services are designed to support the diagnosis, monitoring and management of a wide range of medical conditions.
The company’s imaging capabilities include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET/CT), ultrasound, mammography and X-ray services. Lumexa also provides related radiology and imaging-support services through its outpatient centers and other care-delivery arrangements.
Lumexa Imaging was formerly known as Akumin Inc and adopted the Lumexa Imaging name as part of its corporate rebranding.
See Also
- Five stocks we like better than Lumexa Imaging
- Dave’s Success Has Investors Split
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
Receive News & Ratings for Lumexa Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumexa Imaging and related companies with MarketBeat.com's FREE daily email newsletter.
